Citation Impact
Citing Papers
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
2017 Standout
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
Factors Associated With Severe Late Toxicity After Concurrent Chemoradiation for Locally Advanced Head and Neck Cancer: An RTOG Analysis
2008 Standout
Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene.
2000
P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia.
2000
Multidrug resistance in cancer: role of ATP–dependent transporters
2002 Standout
Gastric cancer
2016 Standout
Nasopharyngeal carcinoma
2005 Standout
Angiosarcoma
2010
Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications
2004 Standout
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2015
Cellular senescence: when bad things happen to good cells
2007 Standout
Recent improvements in outcome for elderly patients with de novo acute myeloblastic leukemia
2001
Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.
1996 Standout
Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976–1993 and on 5098 unselected cases reported in the literature 1974–2001
2002
Acute Myeloid Leukemia in the Elderly
2008
The Outcomes and Costs of Acute Myeloid Leukemia Among the Elderly
2002
Head and neck cancer
2008 Standout
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
2006 Standout
Pharmacodynamics in cancer therapy.
1990
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
2014 Standout
Tumor Metastasis: Molecular Insights and Evolving Paradigms
2011 Standout
Hyperfractionated Irradiation with or without Concurrent Chemotherapy for Locally Advanced Head and Neck Cancer
1998 Standout
Definition and classification of cancer cachexia: an international consensus
2011 Standout
Treatment of head and neck cancer: the role of chemotherapy
1996
Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer
2003 Standout
Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck
2004 Standout
HLA-A2 Restricted, Melanocyte-Specific CD8+ T Lymphocytes Detected in Vitiligo Patients are Related to Disease Activity and are Predominantly Directed Against MelanA/MART1
2001
Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report.
1995
Diclofenac residues as the cause of vulture population decline in Pakistan
2004 StandoutNature
Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)
2003
High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia
2009
Wegener Granulomatosis: An Analysis of 158 Patients
1992 Standout
The pathobiology of mucositis
2004 Standout
Cancer Chemotherapy in Older Adults
1997
Apoptosis
2002 Standout
How to calculate the dose of chemotherapy
2002
Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review
2003 Standout
Soft Tissue Sarcoma: An Update on Systemic Treatment Options for Patients with Advanced Disease
2014
Aspirin alters methotrexate disposition in rheumatoid arthritis patients
1991
Chemotherapy Dosing Part I: Scientific Basis for Current Practice and Use of Body Surface Area
2006
Head and Neck Cancer
1993 Standout
The effect of interruptions and prolonged treatment time in radiotherapy for nasopharyngeal carcinoma
1997
Tumor metastasis: mechanistic insights and clinical challenges
2006 Standout
Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin)
2002
Dose Versus pharmacokinetics for predicting tolerance to 5‐day continuous infusion of 5‐FU
1988
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
2020 Standout
Diclofenac Sodium
1988
Acute Myeloid Leukemia
1999
Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions
2017
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
2016 Standout
Head and Neck Cancer
2001 Standout
Chimeric antigen receptor T-cell therapies for lymphoma
2017
Minireview Magnetically controlled targeted micro-carrier systems
1989
Phase I and Pharmacokinetic Study of the Oral Fluoropyrimidine S-1 on a Once-Daily-for-28-Day Schedule in Patients with Advanced Malignancies
2004
The Activation of Carboxylic Acids via Self-Assembly Asymmetric Organocatalysis: A Combined Experimental and Computational Investigation
2016 StandoutNobel
Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461
2006
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
2013 StandoutNobel
Detection of self-reactive CD8 + T cells with an anergic phenotype in healthy individuals
2014 StandoutScienceNobel
Medroxyprogesterone Acetate Elevation of Nm23-H1 Metastasis Suppressor Expression in Hormone Receptor–Negative Breast Cancer
2005
Treatment of angiosarcoma in Okayama University Hospital : analysis of 18 patients experienced in the past 15 years
2009
Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86
1994
Participation of Patients 65 Years of Age or Older in Cancer Clinical Trials
2003 Standout
Antitumor Antibiotics: Bleomycin, Enediynes, and Mitomycin
2005 Standout
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
2014 Standout
Change of the Death Pathway in Senescent Human Fibroblasts in Response to DNA Damage Is Caused by an Inability To Stabilize p53
2001
Revised Response Criteria for Malignant Lymphoma
2007 Standout
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP
2006 Standout
Ketoprofen: A Review of Its Pharmacologic and Clinical Properties
1986
Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy:results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial
2007
Body Composition as an Independent Determinant of 5-Fluorouracil–Based Chemotherapy Toxicity
2007
Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine
2001
Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial
2001
ICOS+Foxp3+TILs in gastric cancer are prognostic markers and effector regulatory T cells associated withHelicobacter pylori
2016 StandoutNobel
An Intergroup Phase III Comparison of Standard Radiation Therapy and Two Schedules of Concurrent Chemoradiotherapy in Patients With Unresectable Squamous Cell Head and Neck Cancer
2002 Standout
Long-Term Results of RTOG 91-11: A Comparison of Three Nonsurgical Treatment Strategies to Preserve the Larynx in Patients With Locally Advanced Larynx Cancer
2012 Standout
Adjuvant chemotherapy in head and neck cancer
1992
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
CD8+tumor-infiltrating lymphocytes at primary sites as a possible prognostic factor of cutaneous angiosarcoma
2013 StandoutNobel
Chimeric Antigen Receptor Therapy
2018 Standout
Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity
2014
The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials
2001 Standout
Pharmaceuticals of Emerging Concern in Aquatic Systems: Chemistry, Occurrence, Effects, and Removal Methods
2019 Standout
Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data
2000 Standout
Methotrexate in Rheumatoid Arthritis
1987
Cancer Cachexia in the Age of Obesity: Skeletal Muscle Depletion Is a Powerful Prognostic Factor, Independent of Body Mass Index
2013 Standout
Adjuvant Chemotherapy in Head and Neck Cancer.
1992
2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma
2001
World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting—Airlie House, Virginia, November 1997
1999 Standout
Future of Cancer Incidence in the United States: Burdens Upon an Aging, Changing Nation
2009 Standout
Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study
2002
Induction Chemotherapy plus Radiation Compared with Surgery plus Radiation in Patients with Advanced Laryngeal Cancer
1991 Standout
Current status of immunotherapy for the treatment of lung cancer.
2010
The incidence of secondary leukemias.
1999
Stereoselective inhibitory effect of flurbiprofen, ibuprofen and naproxen on human organic anion transporters hOAT1 and hOAT3
2011
Dose translation from animal to human studies revisited
2007 Standout
Works of A. Thyss being referenced
Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma
2009
Pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate in advanced breast cancer patients.
1992
Response to chemotherapy as justification for modification of the therapeutic strategy for pharyngolaryngeal carcinomas
1990
CSF drug levels for children with acute lymphoblastic leukemia treated by 5 g/m2 methotrexate
1990
Population study of dihydropyrimidine dehydrogenase in cancer patients.
1994
Paclitaxel in patients with advanced angiosarcomas of soft tissue: A retrospective study of the EORTC soft tissue and bone sarcoma group
2008
Dihydropyrimidine dehydrogenase activity in cancer patients
1993
Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
1998
Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial
2013
Upfront VIP‐reinforced‐ABVD (VIP‐rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS‐LTP95
2010
Vitiligo-Like Depigmentation and Morpheas after Specific Intralymphatic Immunotherapy for Malignant Melanoma
1992
Renal tolerance of cisplatin in patients more than 80 years old.
1994
High-dose chemotherapy consolidation for chemosensitive advanced soft tissue sarcoma patients: an open-label, randomized controlled trial
2011
Low-energy He/Ne laser in the prevention of radiation-induced mucositis
1999
A multivariate analysis of the survival of patients with aggressive lymphoma: variations in the predictive value of prognostic factors during the course of the disease. Groupe d'Etudes des Lymphomes de l'Adulte.
1998
Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer
1986
Autoimmune hemolytic anemia after nivolumab treatment in Hodgkin lymphoma responsive to immunosuppressive treatment. A case report
2016
Systemic blood levels after intra-arterial administration of microencapsulated mitomycin C in cancer patients
1985
A multivariate analysis of the survival of patients with aggressive lymphoma
1998
Relationship between systemic 5-FU passage and response in colorectal cancer patients treated with intrahepatic chemotherapy
1987
CLINICAL AND PHARMACOKINETIC EVIDENCE OF A LIFE-THREATENING INTERACTION BETWEEN METHOTREXATE AND KETOPROFEN
1986
Toxicity of a combination of ABVD chemotherapy and mediastinal irradiation for Hodgkin's disease patients with massive initial mediastinal involvement.
1988